64results about How to "Strong proliferative activity" patented technology

The invention discloses novel 4-substituted anilinoquinazoline derivatives or pharmaceutically acceptable salts thereof, or polymorphic substances, solvates or stereomers of the 4-substituted anilinoquinazoline derivatives, and a preparation method and application thereof. The 4-substituted anilinoquinazoline compounds have favorable inhibition activities for EGFR and VEGFR-2 in a biological test and have obvious effects in an in-vitro anti-human tumor cell proliferation activity test.

The invention relates to the field of organic synthesis and medicinal chemistry, in particular to a derivative of Cleistanine, a preparation method and application of Cleistanine in preparation of anti-hepatic fibrosis medicines. According to the invention, a novel Cleistanine derivative is synthesized and the invention discloses the preparation method thereof; the pharmacological experiments show that the derivative of Cleistanine has anti-hepatic fibrosis effect and value for developing anti-hepatic fibrosis medicines.

The invention relates to a preparation method and an application of efficient immunocompetent cell CpG-DCIK. The preparation method comprises the following steps: inducing DC cell by use of CpG and cytokine, inducing homologous CIK cell by use of cytokine, and performing mixed culture of the DC cell and CIK cell to obtain a new immune effector cell population, namely oligonucleotide induced dendritic cell and cytokine induced killer cell co-culture cell which is named CpG-DCIK. According to the invention, the DC is induced by use of in-vitro CpG-ODN in combination with cytokine, and then the DC is co-cultured with homologous CIK to obtain an immune effector cell population with higher proliferation activity and cytotoxic activity, and an immune cell population with relatively high antitumor activity can still be induced and amplified for the cases in which a tumor antigen is hardly acquired since the operation opportunity is lost or the cancer is in the late stage and the like, thereby widening the application range of tumor resistance.

The invention discloses application of nobiletin, and particularly discloses application of nobiletin in preparation of health products or medicines for preventing and/or treating oral cancer. Through the anti-proliferation effects of monomeric compounds, namely hesperetin, naringenin and nobiletin, in rutaceae citrus fruits and peels on human oral epidermoid carcinoma cells, the experiments show that the hesperetin, naringenin and nobiletin have an obvious effect on inhibiting proliferation of human oral epidermoid carcinoma cells, and the effect of the nobiletin on inhibiting oral cancer cells is most obvious, so that the nobiletin can be used for preparing health products and medicines with effects on preventing and treating oral cancer and is suitable for large-scale popularization and application.

The invention relates to a drug composition with the effect of anti-lung cancer and an application in preparing anti-lung cancer drug; the raw materials of the drug are as follows by weight portions: 10 to 30 of common selfheal fruit-spike, 10 to 50 of spreading hedyotis herb, 10 to 50 of hairyvein agrimonia herb and bud, 10 to 30 of yerbadetajo herb and 6 to 20 of dogwood. The drug extract is prepared by the following method which comprises the steps of: (1) extracting with 75 percent to 95 percent of alcohol for 1 to 4 times with 1 to 3 hours for each time; (2) carrying out extraction to the drug dreg extracted by the step (1) with 50 percent to 75 percent of alcohol for 1 to 4 times with 1 to 3 hours for each time; (3) combining the extracts of the (1) and (2), recovering the alcohol, reducing pressure and concentrating to obtain macroporous absorption resin column on the concentrated solution, using 40 percent to 60 percent of alcohol for elution to obtain extract I and using 70 percent to 90 percent of alcohol for elution to obtain extract II; and (4) mixing the extract I and the extract II to obtain active components. The application of the drug composition in preparing the drug for anti-lung cancer has stronger capacity to inhibit the proliferative activity of human lung cancer cell SPC-A-1.

The invention discloses a free radical degradation product of abelmoschus manilhot stem leaf polysaccharide and a preparation method thereof. The free radical degradation product of the abelmoschus manilhot stem leaf polysaccharide is composed of mannose, glucose, galactose and arabinose in molar ratio of 0.34:18.56:1.0:0.36 and has the molecular weight of 552.36kDa. The preparation method comprises the following steps: optimizing an extraction separation technology by virtue of a large number of experiments, carrying out water extraction and alcohol precipitation for obtaining crude polysaccharide, then carrying out deproteinization, then purifying by adopting DEAE-52 celluosic resin, so as to obtain high-purity abelmoschus manilhot stem leaf polysaccharide, then degrading by adopting an H2O2-Vc system, and purifying, so that the free radical degradation product of the abelmoschus manilhot stem leaf polysaccharide is obtained. The preparation method disclosed by the invention has the advantages that abandoned abelmoschus manilhot stem leaf resource is fully utilized, waste materials are changed into things of value, the free radical degradation product of the abelmoschus manilhot stem leaf polysaccharide capable of improving immunocompetence is obtained, and sustainable application of traditional Chinese medicine resources can be realized, so that the preparation method has good economic value and great significance for ecological environmental protection.

The invention provides an application of tangeretin in preparation of a medicine or health-care product for preventing and treating oral cancer. Experiments on reproduction prevention of human oral epidermoid carcinoma cells by monomer compounds nobiletin, naringenin and tangeretin in fruits and peels of citrus plants of rutaceae family indicate that the nobiletin, naringenin and tangeretin have certain inhibiting effects on reproduction of human oral epidermoid carcinoma cells, wherein the tangeretin has a most remarkable effect on inhibiting reproduction of oral carcinoma cells, can be used for preparing health-care products having effects of preventing and treating oral carcinoma, and is suitable for large-scale popularization application.

The invention relates to a DC-CIK cell preparation and a preparation method thereof. The DC-CIK cell preparation comprises DC-CIK cells, 20% human serum albumin and a solvent. The preparation method comprises the following preparation steps: 1) collecting peripheral blood into a blood collection bag containing a heparin sodium anticoagulant; 2) adding isopyknic normal saline into a lower-layer redliquid after peripheral blood centrifugation, and carrying out diluting, blowing, beating and uniformly mixing; 3) resuspending and inoculating the peripheral blood mononuclear cells into a T75 culture bottle containing a 5 ml culture medium by using a 10 ml culture medium, and performing culturing in a 5% CO2 incubator at 37 DEG C for 2-6 h; 4) inducting and amplifying DC cells in vitro; 5) inducting and amplifying CIK cells in vitro; 6) co-culturing DC cells and CIK cells; and 7) preparing the DC-CIK cell preparation. The DC-CIK cell preparation has the advantages of high proliferation activity, large cell factor release amount, high cytotoxicity, simplicity, feasibility, low cost and good use effect.

The invention relates to the field of organic synthesis and pharmaceutical chemistry and particularly relates to a Cleistanone O-(piperazinyl)ethyl derivative, a preparation method thereof and use thereof in the preparation of hepatic fibrosis resisting drugs. According to the invention, a novel Cleistanone O-(piperazinyl)ethyl derivative is synthesized, and a preparation method of the novel Cleistanone O-(piperazinyl)ethyl derivative is disclosed. Shown by pharmacological experiments, the Cleistanone O-(piperazinyl)ethyl derivative disclosed by the invention has a hepatic fibrosis resisting effect and has a value in the development of the hepatic fibrosis resisting drugs.

The invention belongs to the technical field of tissue culture, and relates to a tissue culture and rapid propagation research method suitable for industrialized production. The method is summarized and concluded on the basis of experimental research and production for two years on the basis of a new variety of caladium bicolor introduced by Thai, has strong operability and can be completely used for guiding production. According to the invention, the complete rapid induction, multiplication, rooting and seedling hardening propagation method which has high inductivity and propagation multiple and is suitable for industrial production is established for the first time, a batch rapid propagation situation is formed, and the propagation generations, the hormone concentration of a culture medium and the proportion are controlled to change along with the change of the generations, stability, activity and the proliferation coefficient of seedlings are ensured, and the yield and quality are improved; and according to the method, a production manner of simultaneously propagating and rooting is adopted, so that the production cost is reduced, the production progress is accelerated, the propagation coefficient is ensured, the quality of rooted seedlings is ensured, the method is completely suitable for large-scale industrialized production, and the breeding efficiency of the caladium bicolor is greatly improved.

The invention provides a human chondrocyte culture medium, and belongs to the technical field of cells. The invention optimizes a traditional culture medium, and by adding exosomes, fetalbovine serumand penicillin-streptomycin into a basal culture medium, chondrocyte proliferation can be effectively promoted, dedifferentiation of human chondrocytes is prevented, transformation of the human chondrocytes into fibrocyte-like phenotypes is prevented, and the single-layer culture passage number is increased. The invention also provides a method for isolating culture of the human chondrocytes by using the above-mentioned culture medium, and normal chondrocytes cultured to the sixth passage can be obtained.

The invention relates to the field of organic synthesis and drug chemicals. The invention discloses a composition prepared from O-(benzimidazole) ethyl derivative (III) and O-(dichloroethylamino) ethyl derivative (IV) of Psiguadial A according to mass ratio of 20: 80 and a preparation method of the composition by mixing above compounds according to mass ratio of 20: 80. The pharmacological experiment indicates that the composition provided by the invention can significantly inhibit the NIH/3T3 propagation and fibroblast propagation induced by transforming growth factor-beta 1 when its content is 20 ug/ml, and the composition has the anti-hepatic fibrosis effect; therefore, the invention further provides the application of the composition prepared from O-(benzimidazole) ethyl derivative (III) and O-(dichloroethylamino) ethyl derivative (IV) of Psiguadial A according to mass ratio of 20: 80 in preparing the anti-hepatic fibrosis drugs.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, in particular to a composition, a preparation method and use of the composition in preparation of an anti-liver fibrosis medicament. The invention discloses a composition and a preparation method thereof. As proved by pharmaceutical experiments, the composition has an anti-liver fibrosis function and a value in developing the anti-liver fibrosis medicament.

The invention relates to the field of organic synthesis and medicinal chemistry, and particularly relates to a cleistanone derivative, and a preparation method and an application thereof in preparation of anti-hepatic fibrosis drugs. The new cleistanone derivative is synthesized, and the preparation method is disclosed. Pharmacological experiments indicate that the cleistanone derivative has an anti-hepatic fibrosis effect and has a value of development of the anti-hepatic fibrosis drugs.

The invention discloses an application of O-(dichloroethylamino)-ethyl and O-(bis(2-methylthioethyl) amino)ethyl derivatives of Artalbic acid in preparation of an anti-liver fibrosis medicine, relating to the fields of organic synthesis and pharmaceutical chemistry. The invention discloses and provides a composition composed of O-(dichloroethylamino)-ethyl and O-(bis(2-methylthioethyl) amino)ethyl derivatives of Artalbic acid in a mass ratio of 30:70 and a method for preparing the composition by mixing the compounds in a mass ratio of 30:70. Pharmacological experiments show that the composition provided by the invention can obviously inhibit NIH/3T3 proliferation and transforming growth factor-beta 1 induced fibroblast proliferation at 20mu g/ml and has an anti-liver fibrosis effect. Therefore, the invention also provides an application of the composition composed of the O-(dichloroethylamino)-ethyl and O-(bis(2-methylthioethyl) amino)ethyl derivatives of Artalbic acid in a mass ratio of 30:70 in preparation of the anti-liver fibrosis medicine.

The invention relates to the field of organic synthesis and medicinal chemistry, and provides a composition formed by O-(piperazinyl)ethyl derivatives (III) and O-(1H-tetrazole-based)ethyl derivatives (IV) of Psiguadial A according to the mass ratio of 10:90 and a method for preparing the composition by mixing the compouds according to the mass ratio of 10:90. Pharmacological experiments show that the composition can remarkably inhibit NIH/3T3 proliferation and transforming growth factor-beta1 induced fibroblast proliferation at 20ug/ml, and has a liver fibrosis resisting function, and therefore the invention further provides application of the composition formed by the O-(piperazinyl)ethyl derivatives (III) and the O-(1H-tetrazole-based)ethyl derivatives (IV) of Psiguadial A according to the mass ratio of 10:90 in preparing medicine for resisting liver fibrosis. The formula is shown in the description.

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition 67083001030512, a preparation method of the composition 67083001030512, and application of the composition 67083001030512 to a drug for resisting liver fibrosis, and discloses the composition 67083001030512 and the preparation method. Pharmacological experiments show that the composition 67083001030512 plays a role in resisting liver fibrosis, thereby having a high value on development of the drug for resisting liver fibrosis.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry. The invention discloses and provides a composition which is prepared from an O-(benzimidazolyl)ethyl derivative (III) and an O-(morpholinyl)ethyl derivative (IV) of Atropurpuran in a mass ratio of 65 to 35, and a method for preparing the composition by mixing the compounds in the mass ratio of 65 to 35. As proved by a pharmacology experiment, the composition provided by the invention can remarkably restrain NIH/3T3 multiplication and fibroblast proliferation induced by transforming growth factor-beta1, and has an anti-hepatic fibrosis effect. The invention further provides application of the composition prepared by mixing the O-(benzimidazolyl)ethyl derivative (III) and the O-(morpholinyl)ethyl derivative (IV) of the Atropurpuran in the mass ratio of 65 to 35 to preparation of an anti-hepatic fibrosis medicament. (The composition is shown in the description.).

The invention relates to the fields of organic synthesis and medicinal chemistry, in particular to a composition 77092202050623, a preparing method of the composition 77092202050623 and the application of the composition 77092202050623 in preparing anti-hepatic fibrosis drugs. Pharmacology experiments show that the composition 77092202050623 can resist hepatic fibrosis and can be used for developing anti-hepatic fibrosis drugs.

The invention relates to the field of organic synthesis and drug chemicals. The invention discloses a composition prepared from O-(imidazolyl)ethyl derivative (III) and O-(dihydroxyethylamino)ethyl derivative (IV) of Psiguadial A according to mass ratio of 15: 85 and a preparation method of the composition by mixing above compounds according to mass ratio of 15: 85. The pharmacological experiment indicates that the composition provided by the invention can significantly inhibit the NIH/3T3 propagation and fibroblast propagation induced by transforming growth factor-beta 1 when its content is 20 ug/ml, and the composition has the anti-hepatic fibrosis effect; therefore, the invention further provides the application of thecomposition prepared from O-(imidazolyl)ethyl derivative (III) and O-(dihydroxyethylamino)ethyl derivative (IV) of Psiguadial A according to mass ratio of 15: 85 in preparing the anti-hepatic fibrosis drugs.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and discloses a composition composed of the O-(triazolyl)ethyl derivative and the O-(1H-tetrazolyl)ethyl derivative of Artalbic acid according to a mass ratio of 20:80, and a method for preparing the composition by mixing the O-(triazolyl)ethyl derivative and the O-(1H-tetrazolyl)ethyl derivative of Artalbic acid according to the mass ratio of 20:80. Pharmacologic experiments show that the composition can substantially inhibit NIH/3T3 propagation and transforming growth factor-beta 1 induced fibroblast propagation at 20[mu]/ml, and has an anti-liver fibrosis effect. The invention also provides a use of the composition composed of the O-(triazolyl)ethyl derivative and the O-(1H-tetrazolyl)ethyl derivative of Artalbic acid according to a mass ratio of 20:80 in the preparation of the anti-liver fibrosis medicines.

The invention relates to the fields of organic synthesis and pharmaceutical chemistry, and discloses and provides a composition prepared from Virosaine A piperazinyl derivative and Virosaine A imidazolyl derivative at the weight ratio of 25 to 75, and a method for preparing the composition by mixing the two compounds at the weight ratio of 25 to 75. The pharmacological experiment proves that the composition provided by the invention at 20 [mu] g/ml can obviously inhibit the proliferation of NIH/3T3 and the proliferation of fibroblasts induced by transforming growth factor-beta 1, and has the effect of resisting hepatic fibrosis, and therefore, the invention further provides the applications of the composition prepared from the Virosaine A piperazinyl derivative and the Virosaine A imidazolyl derivative at the weight ratio of 25 to 75 in preparing medicines for resisting hepatic fibrosis.

The invention relates to a Fakalin alcohol compound enantiomer, a method for synthesizing the same and application of the Fakalin alcohol compound enantiomer. Structural general formulas of the Fakalin alcohol compound enantiomer are shown as formulas I and II. Zinc reagents, halides, chiral BINOL (binaphthol) reagents and Ti reagents are mixed with one another, asymmetric addition is carried outon aldehyde by 1, 3-diyne compounds under specific conditions, Fakalin alcohol compound enantiomers with serial specific structures can be synthesized in a high-selectivity manner, one of every two corresponding enantiomers is high in HeLa tumor cell anti-proliferation activity, and mixed components with different proportions of every two corresponding enantiomers and IC 50 values of the antitumorcell activity of the components have linear relations. The Fakalin alcohol compound enantiomer, the method and the application have the advantages that synthetic reaction conditions are mild, raw materials for chiral reagents are simple and are easily available, the Fakalin alcohol compound enantiomer and the method are high in stereo-selectivity, and the method is suitable for preparing chiral Fakalin alcohol compounds and producing the chiral Fakalin alcohol compounds on a large scale.